In GC, studies have shown that high SMYD3 expression promotes GC cell proliferation, migration, and invasion through ATM signaling, and that SMYD3 may become a therapeutic target for GC patients (Wang et al., 2017). This evidence concerns the gene SMYD3 and gastric cancer.